Atlas Trials

Medical Oncology

20 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Medical Oncology

RecordFirmDate
Ezra Faster Scan Study (NCT05385718)Ezra AI, Inc.2022-06-01
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies (NCT05356182)State University of New York at Buffalo2022-05-04
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy (NCT05359848)State University of New York at Buffalo2022-04-15
Onco-haematology Vigilance Card (NCT04931329)University Hospital, Limoges2021-11-08
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole (NCT02824042)Bayer2016-09-07
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors (NCT02639091)Bayer2016-02-03
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel (NCT02439346)Bayer2015-06-15
A Problem-Solving Intervention for Family Caregivers in Palliative Oncology (NCT02427490)University of Missouri-Columbia2015-04-01
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel (NCT02366949)Bayer2015-02-27
The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance (NCT02327806)Tel-Aviv Sourasky Medical Center2015-01-01
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients (NCT02253420)Bayer2014-10-08
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel (NCT02138812)Bayer2014-05-09
Transpulmonary Thermodilution Using an Implented Central Venous Access Port (NCT02357953)Gustave Roussy, Cancer Campus, Grand Paris2012-10-01
Results From a Health System-wide Implementation of a Quality of Life Questionnaire (NCT02906423)Allina Health System2012-07-01
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 (NCT01409135)Astellas Pharma Inc2011-07-11

Track Medical Oncology automatically

Every clearance here is in the API, with alerts when new ones post.